Bristol-Myers Squibb Company(BMY)
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Latest News & Analysis
Bristol Myers Breyanzi MZL Approval Extends CAR T Franchise Momentum
FDA grants fifth U.S. indication with 95.5% response rate, reinforcing oncology execution one day after neuroscience trial setback disclosure.
Bristol Myers ADEPT-2 Trial Irregularities Test Psychiatric Franchise Ambitions
Site execution issues delay Alzheimer's psychosis readout to 2026, but trial continuation preserves Karuna acquisition optionality and neuroscience strategy.
Bristol Myers Faces $6.7B Celgene Lawsuit as ASH Data Tests Pipeline Credibility
Federal judge allows breach-of-contract claims over delayed Breyanzi approval while December ASH presentations showcase next-generation hematology assets.
Breyanzi EU Mantle Cell Lymphoma Approval Reinforces Bristol Myers Franchise
European Commission grants fourth Breyanzi indication with 82.7% response rate, reinforcing oncology execution despite pipeline challenges.
Milvexian's ACS Failure Tests Bristol Myers' Pipeline Resilience Amid Multiple Setbacks
Bristol Myers halts Phase 3 Librexia ACS trial after interim futility signal, signaling R&D challenge but core franchises and capital discipline remain intact.
Bristol-Myers Squibb Strategic Reorganization and Pipeline Developments
Detailed analysis of BMY's reorganization, pipeline developments, and financial challenges amid patent expirations and a strong dividend strategy.
Bristol Myers Squibb: Pipeline Progress Amidst Patent Expiration Challenges
Intraday update on BMY’s breakthroughs in immuno‐oncology, robust pipeline data, and strategic financial moves.
Bristol Myers Squibb: Market Developments and Strategic Outlook
Explore the latest developments, trials, and licensing agreements at BMY, impacting its competitive landscape and market outlook.
Bristol Myers Squibb: Pipeline Progress & Patent Cliff Challenges
Bristol Myers Squibb navigates pipeline advancements amid patent cliff challenges, with Opdivo, Sotyktu, and Breyanzi updates influencing investor sentiment.
Bristol Myers Squibb: Pipeline Developments, Market Impact, and Industry Trends
Bristol Myers Squibb (BMY) is expanding its pipeline with strategic collaborations and robust drug data amidst competitive industry challenges.
Bristol Myers Squibb: Navigating Patent Cliffs, Driving Growth
Bristol Myers Squibb navigates patent expirations with new drugs, strategic partnerships, and cost cuts. FDA reviews Opdivo/Yervoy, Breyanzi sales surge, and BioArctic collaborates.
Bristol-Myers Squibb (BMY): Oncology Pipeline, Dividend Strategy, and Future Outlook
Bristol-Myers Squibb (BMY) navigates oncology advancements, pipeline challenges, and financial pressures. Strategic partnerships and innovation balance stability. Market rotation favors dividend stocks.
Bristol Myers Squibb (BMY): FDA Approvals, Oncology Growth, and Dividend Analysis
Bristol Myers Squibb (BMY) navigates patent expirations, oncology growth, and strategic collaborations. FDA actions and dividend appeal shape investor attention.
Bristol-Myers Squibb (BMY): Navigating Patent Expirations and Pipeline Development
Bristol-Myers Squibb (BMY) navigates patent expirations, pipeline development, and a shifting market. FDA reviews, oncology advancements, and dividend strategies shape its future.
Bristol-Myers Squibb (BMY): Opdivo Approval, Acquisitions, and Market Outlook
Bristol-Myers Squibb (BMY) navigates patent expirations with strategic acquisitions and cost-cutting. Opdivo's EU approval and pipeline expansion offer growth potential.
Bristol-Myers Squibb (BMY): Navigating Revenue Transition and Growth
Bristol-Myers Squibb (BMY) navigates revenue transition with new drugs, cost cuts. Sotyktu's success & Opdivo's EU approval offer growth. A defensive, high-yield dividend stock.
Bristol Myers Squibb (BMY): Oncology Strategy and Financial Outlook
Bristol Myers Squibb (BMY) navigates strategic acquisitions, clinical trial successes, and cost-cutting to maintain market position and dividend sustainability.
Bristol-Myers Squibb (BMY): Acquisition Strategy, Dividend Dilemma, and Growth Prospects
BMY faces a complex landscape with its acquisition of 2seventy bio under scrutiny, Sotyktu showing promise, and questions arising over dividend sustainability.
Bristol-Myers Squibb (BMY): Breyanzi Approval, 2seventy Bio Deal & Dividend Strategy
Bristol-Myers Squibb (BMY) navigates acquisitions, regulatory approvals, and market dynamics. A look at Breyanzi's approval, the 2seventy bio deal, and dividend strategy.
Bristol-Myers Squibb (BMY): Navigating Challenges and Driving Growth
Bristol-Myers Squibb (BMY) faces Revlimid LOE but focuses on growth portfolio expansion and cost-cutting. Breyanzi's EU approval is a key growth driver.
Bristol-Myers Squibb (BMY): Opdivo's European Approval, Debt Concerns, and Investor Outlook
Bristol-Myers Squibb (BMY) navigates Opdivo's European expansion amid debt concerns. A defensive stock with value potential, yet faces market volatility. Investors should weigh these factors.
Bristol Myers Squibb (BMY): Opdivo, Dividends, and Market Challenges
Bristol Myers Squibb (BMY) navigates market volatility with Opdivo's growth, cost cuts, and dividend focus amidst revenue decline forecasts. Key insights for investors.
Bristol-Myers Squibb (BMY): Dividend Safety, Patents, and FDA
Bristol-Myers Squibb (BMY) navigates patent expirations, tariff threats, and market volatility. A data-driven analysis of BMY's financials and FDA approvals.
Bristol-Myers Squibb: Navigating Patent Cliffs with Strategic Innovation
Bristol-Myers Squibb navigates a complex period with clinical triumphs like Breyanzi's TRANSCEND FL data amidst the looming Eliquis patent cliff and strategic shifts.
Bristol-Myers Squibb (BMY): Pipeline Advances & Financial Dynamics
Bristol-Myers Squibb (BMY) showcases strong pipeline advancements, particularly with Sotyktu and OncoACP3, amidst Q2 2025 earnings forecasts.
Bristol Myers Faces Antitrust Challenge Over Pomalyst
Cigna's antitrust lawsuit against Bristol Myers Squibb over Pomalyst alleges patent fraud, sham litigation, and pay-for-delay tactics, impacting BMY's market position.
Bristol-Myers Squibb Company (BMY) Strategic Pivot and Financial Health Analysis
Explore Bristol-Myers Squibb's recent stock trends, strategic partnerships, oncology pipeline growth, and dividend sustainability amid patent expirations.
Bristol-Myers Squibb Company (BMY) Strategic Growth and Financial Analysis Q2 2025
Bristol-Myers Squibb's strategic initiatives and new drug launches drive revenue growth, offsetting legacy patent cliffs while maintaining strong financial health.
Bristol-Myers Squibb (BMY) Latest Financial Analysis and Growth Strategy Insights
Explore Bristol-Myers Squibb's recent financial performance, strategic growth drivers, and implications for investors amid legacy drug declines and pipeline expansions.
Bristol-Myers Squibb Growth Transition: Navigating Patent Cliffs and Sustaining Dividends | Monexa AI Analysis
Explore Bristol-Myers Squibb's strategic shift balancing legacy declines with new drug growth, financial health, and dividend sustainability amid evolving market dynamics.
Bristol-Myers Squibb Company (BMY) Latest Financial Analysis & Strategic Growth Update
Explore Bristol-Myers Squibb's recent financial results, pipeline advances, and strategic pivots shaping its growth amid patent challenges and competitive pharma markets.
Bristol-Myers Squibb Company (BMY) Q2 2025 Earnings Preview and Strategic Growth Insights
Detailed analysis of Bristol-Myers Squibb's Q2 2025 earnings outlook, pipeline catalysts, patent cliff challenges, and financial metrics shaping investor decisions.
Bristol-Myers Squibb Company (BMY) Growth Strategy and Financial Update Amid BioNTech Partnership
Explore Bristol-Myers Squibb's strategic pivot with the $3.5B BioNTech deal, Q2 earnings beat, and pipeline advances shaping its growth and valuation.
Bristol-Myers Squibb Company (BMY) Strategic Pivot with Eliquis Direct-to-Patient Program and Financial Insights
Bristol-Myers Squibb's new Eliquis direct-to-patient program offers 40%+ discounts, reshaping market access amid strong financial shifts and competitive pressures.
Bristol-Myers Squibb (BMY): Financials, Pipeline, and Strategic Shifts Analyzed
Deep dive into Bristol-Myers Squibb's recent Sotyktu trial success, OncoACP3 licensing deal, financials, and strategic partnerships shaping its market position.
Bristol-Myers Squibb Company: Strategic Immunology Venture and Financial Analysis
Bristol-Myers Squibb partners with Bain Capital to form a new immunology venture, reshaping its R&D focus amid significant financial shifts and market dynamics.
Bristol-Myers Squibb Company (BMY) Q2 2025 Earnings and Strategic Response to US Drug Pricing Policies
Bristol-Myers Squibb's strong Q2 2025 earnings and strategic pipeline development underscore resilience amid evolving US drug pricing regulations.
Bristol-Myers Squibb Company (BMY) Patent Cliff Strategy and Financial Resilience Analysis
Comprehensive analysis of Bristol-Myers Squibb's patent cliff challenges, financial performance, and strategic initiatives shaping its future growth trajectory.
Bristol-Myers Squibb (BMY) Deep Dive: Navigating Patent Cliffs with Pipeline Innovation and Dividend Resilience
Explore Bristol-Myers Squibb's strategic response to patent expirations, leveraging AI-driven pipeline growth and strong cash flow to sustain dividends and long-term value.
Bristol-Myers Squibb's Strategic Immunology Venture and Financial Update - Monexa AI
Explore Bristol-Myers Squibb's $300M immunology partnership with Bain Capital, its impact on pipeline, Q2 earnings outlook, and financial health analysis.
Bristol‑Myers Squibb: Cash Strength, Big Acquisition Charges and an Oncology Pivot
BMY posted **$48.3B revenue** and a **$8.95B GAAP loss in 2024** while producing **$13.94B free cash flow** — and Izalontamab Brengitecan just earned FDA Breakthrough status.
Bristol-Myers Squibb: Cash-Rich Transition Amid a 2024 Net Loss
BMY posted a **-$8.95B** 2024 net loss while generating **$13.94B** free cash flow; growth and legacy portfolios sat roughly equal in Q1 2025 at ~$5.6B each.
Bristol‑Myers Squibb (BMY): Cash‑Strong but Transitioning — The Numbers Behind the Pivot
BMY reported a **FY2024 GAAP net loss of -$8.95B** while generating **$15.19B in operating cash flow** and **$13.94B free cash flow**, highlighting a capital‑intensive pivot toward new launches and acquisition activity.
Bristol-Myers Squibb: Strategic Shifts and Financial Landscape in 2025
Bristol-Myers Squibb navigates strategic shifts with key partnerships and regulatory wins, balancing robust pipeline investment against recent financial fluctuations.
Bristol-Myers Squibb: Dividend Durability Under the 2028–2030 Patent Cliff
Bristol-Myers Squibb posted FY2024 free cash flow of **$13.94B** even as GAAP net income swung to **- $8.95B**; the next test is whether new growth drugs can cover the 2028–2030 patent erosion.
Bristol-Myers Squibb (BMY): Cash Flow Strength Masks a Debt-Fueled Transition
BMS swung to a **$8.95B** net loss in 2024 after **$20.72B** of acquisition outlays, yet generated **$13.94B** of free cash flow and pushed net debt to **$40.85B**.